| Product Name | VU0467154 |
| Description |
M4 Receptor Agonist |
| Purity | >98% (HPLC) |
| CAS No. | 1451993-15-9 |
| Molecular Formula | C17H15F3N4O3S2 |
| Molecular Weight | 444.45 |
| Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
| Storage Temperature | -20ºC |
| Shipping Temperature | Blue Ice or 4ºC |
| Product Type | Inhibitor |
| Solubility | Soluble in DMSO |
| Source | Synthetic |
| Appearance | Tan Solid |
| SMILES | O=S(C1=CC=C(C=C1)CNC(C2=C(N)C 3=C(C)C(C)=NN=C3S2)=O)(C(F)(F)F)= O |
| Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection |
| Cite This Product | VU0467154 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-184) |
| Alternative Names | 5-amino-3,4-dimethyl-N-(4-((trifluoromethyl)sulfonyl)benzyl)thieno[2,3-c]pyridazine-6-carboxamide |
| Research Areas | Neurodegeneration, Neuroscience, Neurotransmitter Receptors, NMDA Receptors |
| PubChem ID | PMC4324418 |
| Scientific Background | VU0467154 is an allosteric activator of the M4 muscarinic acetylcholine receptor, offering a novel approach to treating psychotic symptoms in schizophrenia and other neuropsychiatric disorders. In preclinical models, it reverses stimulant-induced behavioral deficits and enhances associative learning and memory. Its ability to modulate cholinergic signaling positions it as a promising candidate for cognitive enhancement and therapeutic intervention in disorders involving impaired synaptic plasticity and neurotransmission, such as Alzheimer’s disease and schizophrenia. |
| References | 1. Bubser M., et. al. (2014) ACS Clinical Neuroscience 5: 920 - 942. |
StressMarq Biosciences :
Based on validation through cited publications.